Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest update is out from Amplia Therapeutics ( (AU:ATX) ).
Amplia Therapeutics has reported updated interim data from its Phase 2a ACCENT trial in metastatic pancreatic cancer, presented at the 2026 ASCO Gastrointestinal Cancer Symposium. The trial, which evaluates narmafotinib in combination with standard chemotherapies gemcitabine and Abraxane, shows a progression-free survival of 7.7 months versus 5.5 months for chemotherapy alone and an overall response rate of 35%, rising to 42% including unconfirmed responses, while maintaining a safety profile comparable to chemotherapy alone. Management says the ASCO GI presentation reinforces Amplia’s positioning among leading oncology developers and highlights the potential of narmafotinib to improve outcomes in advanced pancreatic cancer, complementing its broader clinical strategy that includes the newly opened AMPLICITY trial combining narmafotinib with FOLFIRINOX.
The most recent analyst rating on (AU:ATX) stock is a Hold with a A$0.17 price target. To see the full list of analyst forecasts on Amplia Therapeutics stock, see the AU:ATX Stock Forecast page.
More about Amplia Therapeutics
Amplia Therapeutics Limited is an Australian pharmaceutical company developing a pipeline of Focal Adhesion Kinase (FAK) inhibitors targeting cancer and fibrosis. The company focuses on fibrotic cancers such as pancreatic and ovarian cancer, as well as chronic diseases like idiopathic pulmonary fibrosis, with its lead candidate narmafotinib (AMP945) positioned as a best-in-class FAK inhibitor for solid tumours.
Average Trading Volume: 903,683
Technical Sentiment Signal: Buy
Current Market Cap: A$79.53M
For detailed information about ATX stock, go to TipRanks’ Stock Analysis page.